Personalizing Asthma Management for the Clinician. (2017)

• Record Type: Book
• Other Names: Szefler, Stanley J
• Contents: Front Cover; Personalizing Asthma Management for the Clinician; Personalizing Asthma Management for the Clinician; Copyright; List of Contributors; Preface; Foreword; Introduction; BACK TO THE BOOKS; RAPIDLY DEVELOPING SCIENCE; HEALTHCARE CHANGES; WHAT CAN YOU EXPECT TO LEARN?; Contents; 1 -- A Population Management Model of Asthma and Allergy: Case Finland; INTRODUCTION; FINNISH HEALTHCARE SYSTEM; INCREASE IN PREVALENCE AND NEED FOR TREATMENT; GETTING STARTED-ASTHMA PROGRAM STRATEGY; Paradigm Change; Early Detection, Timely Treatment; Burden Decreased; Costs Are Down ASTHMA AND ALLERGY EPIDEMIC REMAINEDALLERGY PROGRAM STRATEGY; Contact-Person Network; Measuring Outcomes; ARE WE ON THE RIGHT TRACK?; LESSONS LEARNED; Some Tips; CONCLUSIONS; REFERENCES; 2 -- Population Health Management: A Systematic Approach to Asthma Care in a Pediatric Network of Care; INTRODUCTION; MANAGING A POPULATION OF CHILDREN WITH ASTHMA; Define the Priorities and Abilities of the Network of Care Leaders; Define the Geographic Region of Care; Identify Key Stakeholders and Assess the Needs; Identify the Target Population; Set Priorities; Build a Team and a Steering Committee Collect Baseline Health DataTeam Education; IMPLEMENTATION EXAMPLE: CHILDREN'S HOSPITAL COLORADO; KEYS TO SUCCESS; Summary; REFERENCES; 3 -- Management of Severe Asthma in Adults: New Insights; INTRODUCTION; DEFINITION OF SEVERE ASTHMA; EPIDEMIOLOGY OF SEVERE ASTHMA; KEY FEATURES OF THE ASSESSMENT AND PATHOPHYSIOLOGY OF ASTHMA; TREATMENT; Anticholinergics; EOSINOPHILIC ASTHMA AND THE BIOLOGICS; Reslizumab; Benralizumab; Tralokinumab; Dupilumab; Bronchial thermoplasty; Macrolide antibiotics; SUMMARY AND FUTURE CONSIDERATIONS; REFERENCES 4 -- Management and Prevention of Severe Asthma in ChildrenINTRODUCTION; DEFINITION OF SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS; KEY FEATURES OF SEVERE ASTHMA IN CHILDREN; EARLY IDENTIFICATION OF SEVERE ASTHMA IN YOUNGER CHILDREN; ESTABLISHED MEDICATIONS FOR THE TREATMENT OF SEVERE ASTHMA IN CHILDREN; PHENOTYPE-DIRECTED TREATMENT STRATEGIES; Eosinophil-Predominant Type 2 Inflammatory Phenotype; Neutrophil-Predominant Inflammatory Phenotype; OTHER EMERGING TREATMENTS; FUTURE DIRECTIONS AND NEEDS; REFERENCES; 5 -- Exhaled Nitric Oxide as a Biomarker for Asthma Management; INTRODUCTION HOW IS NITRIC OXIDE MEASURED AND HOW IS IT PRODUCED?FRACTION OF EXHALED NITRIC OXIDE IS A DIAGNOSTIC TEST FOR ASTHMA; FRACTION OF EXHALED NITRIC OXIDE AND WHEEZING PHENOTYPES; FRACTION OF EXHALED NITRIC OXIDE IS A DIAGNOSTIC TEST FOR ASTHMA; FRACTION OF EXHALED NITRIC OXIDE AND WHEEZING PHENOTYPES; FRACTION OF EXHALED NITRIC OXIDE IS A MEASURE OF ASTHMA SEVERITY AND CONTROL; FRACTION OF EXHALED NITRIC OXIDE IS A PREDICTOR OF ASTHMA RELAPSE DURING INHALED GLUCOCORTICOID REDUCTION; FRACTION OF EXHALED NITRIC OXIDE IS A PREDICTOR OF ASTHMA EXACERBATIONS
• Publisher Details: Place of publication not identified : Elsevier Health Sciences
• Publication Date: 2017
• Extent: 1 online resource ()
• Subjects: 616.2/3806; Asthma -- Treatment; HEALTH & FITNESS / Diseases / General; MEDICAL / Clinical Medicine; MEDICAL / Diseases; MEDICAL / Evidence-Based Medicine; MEDICAL / Internal Medicine; Electronic books
• Languages: English
• ISBNs: 9780323497084
• Related ISBNs: 032349708X; 0323485529; 9780323485524
• Notes: Note: Description based on print version record.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.